TEVA (Teva Pharmaceutical Industries Limited) stock: $38.98, $45.42B market cap, $3.65B cash, $46.27B EV, $45.42B fully diluted market cap. Next expected readout: Sep-26. Lead program: Fp/ABS (Asthma), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$46,268.2M
Balance sheet
| Cash | $3,655.0M |
|---|
| Debt | $4,500.0M |
|---|
| Net cash | -$845.0M |
|---|
| Enterprise value | $46,268.2M |
|---|
| Basic shares | 1,165.0M shares |
|---|
| Fully diluted shares | 1,165.3M shares |
|---|
| Fully diluted market cap | $45,423.2M |
|---|
| Cash per share | $3.14 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading TEVA daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Oct 31 - Dec 12 | FP | Phase 3 | Asthma | — |
| Dec 12, 2026 - Jan 23, 2027 | TEV-56248 | Phase 3 | Asthma | — |
| Feb 26 - Apr 9 | TEV-56286 | Phase 1 | Healthy Volunteers | — |
| Oct 27 - Dec 8 | TEV-56286 | Phase 2 | Multiple System Atrophy | — |
| Jun 7 - Jul 19 | TEV-53408 | Phase 1 | Vitiligo | — |
| Jun 20 - Aug 1 | Duvakitug | Phase 3 | Ulcerative Colitis | — |
| Nov 2 - Dec 14 | Duvakitug | Phase 3 | Ulcerative Colitis | — |
| Jun 14 - Jul 26 | TEV-56286 | Phase 2 | Multiple System Atrophy | — |
| Jun 25 - Aug 6 | Duvakitug | Phase 3 | Crohn's Disease | — |
| Jul 7 - Aug 18 | TEV-56278 | Phase 1 | Advanced Solid Tumors | — |
| Sep 24 - Nov 5 | Duvakitug | Phase 3 | Crohn's Disease | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
olanzapine LAI
Phase 3 · Active Modality: long-acting injectable
Aliases TEV-749
Partnerships MedinCell: development and commercialization of long-acting injectable products; Teva leads clinical development and regulatory process
Status note Phase 3 completed. NDA submitted December 2025 (accepted February 2026); EMA MAA accepted May 2026.
ecopipam
Phase 3 · Active Modality: small molecule
Aliases EBS-101
Target dopamine D1 receptor
Partnerships Emalex Biosciences: Teva acquired all outstanding shares June 2026 (~$700M); former shareholders eligible for milestones up to $200M plus royalties
Indications- Tourette syndrome (pediatric) (Phase 3)
Status note Phase 3 completed. NDA submitted to FDA June 18, 2026.
duvakitug
Phase 3 · Active Modality: monoclonal antibody
Aliases TEV-574
Target TL1A
Partnerships Sanofi: collaboration (upfront $500M; $250M milestones per indication achieved Q4 2025); Sanofi leads Phase 3 development; 50/50 development cost and profit/loss share in major markets. Blackstone Life Sciences: up to $400M development funding
Indications- Ulcerative colitis (Phase 3)
- Crohn's disease (Phase 3)
- Hidradenitis suppurativa (Stage not disclosed)
- Fibrostenotic Crohn's disease (Stage not disclosed)
Status note Phase 3 studies for ulcerative colitis and Crohn's disease initiated October 2025 by Sanofi and Teva.
emrusolmin
Phase 2 · Active
Aliases TEV-286
Partnerships Modag GmbH: exclusive global license to develop, manufacture and commercialize
Indications- Multiple System Atrophy (MSA) (Phase 2)
- Parkinson's disease (Stage not disclosed)
Status note Phase 2 clinical trial for MSA initiated Q3 2024. FDA Fast Track designation for MSA (September 2025).
TEV-287
Phase 1 · Active
Partnerships Modag GmbH: collaboration
Indications- Parkinson's disease (Phase 1)
Status note Phase 1 clinical trial initiated Q2 2025.
TEV-408
Phase 1 · Active Modality: monoclonal antibody
Target IL-15
Partnerships Royalty Pharma: funding agreement (up to $75M R&D funding; option for additional $425M based on Phase 2b results)
Indications- Vitiligo (Phase 1)
- Celiac disease (Stage not disclosed)
Status note Phase 1b results completed; advancing to Phase 2b in vitiligo.
DARI
Phase 3 · Active Modality: inhaled combination
Aliases Dual-Action Asthma Rescue Inhaler, ICS-SABA
Partnerships Launch Therapeutics: clinical collaboration to accelerate the clinical research program. Abingworth: development funding
Status note Phase 3 trial ongoing; targeted initial enrollment levels in adult and pediatric populations achieved by end 2025.
BD9
Stage not disclosed · Active Modality: multibody
Aliases TEV-325
Partnerships Biolojic Design: Teva received exclusive rights to develop, manufacture and globally commercialize
Indications- Asthma (Stage not disclosed)
- Atopic dermatitis (Stage not disclosed)
Status note Early-stage multibody with potential indications including asthma and atopic dermatitis.
Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.